TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9006746
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg oral, twice daily on days 2/3 followed by placebo on days 4-6)
Study: 9006746
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg oral, twice daily on days 2-6)
Study: 9006746
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg oral, twice daily) plus Dexamethasone (4 mg oral, twice daily on days 2-6)
Study: 31210529
Drug: Tofogliflozin 20
Normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Tofogliflozin 20 mg/day
Study: 24725442
Drug: Apixaban 2.5
Normalized name: apixaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 2.5 mg
Study: 24725442
Drug: Apixaban 5
Normalized name: apixaban 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban 5 mg
Study: 18847418
Drug: Calcium compounds
Normalized name: Calcium compounds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium compounds
Study: 10871712
Drug: MDMA (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (1.5 mg/kg p.o.)
Study: 10871712
Drug: Haloperidol (1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (1.4 mg i.v.)
Study: 9347436
Drug: Oxycodone 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 0.04 mg/kg
Study: 9347436
Drug: Tramadol 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 0.6 mg/kg
Study: 8471816
Drug: Combined preoperative
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined preoperative treatment (group 1)
Study: 28029926
Drug: n‐3 LCPUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 LCPUFA (fish oil) 2.4 g per day
Study: 24970858
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (2,000 mg)
Study: 24970858
Drug: Control (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (identical soy/corn oil capsules)
Study: 22861493
Drug: Medication and
Normalized name: CVS Health Medication and Topical Refill Pouch KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication and clinical records
Study: 18318945
Drug: Amoxicillin (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (oral, twice daily for 5 days)
Study: 18318945
Drug: Ceftriaxone (intramuscular,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (intramuscular, once daily for 2 days)
Study: 16704037
Drug: TB treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TB treatment for 4 months under direct observation after 2 months of initial treatment
Study: 16704037
Drug: Extent of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extent of disease and treatment failure/relapse
Study: 10965418
Drug: benidipine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: benidipine (4 mg/day)
Study: 1335646
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of immune globulin (Ig) and hepatitis A vaccine
Study: 1335646
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine alone
Study: 1335646
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Ig and vaccine
Study: 28474341
Drug: Dexamethasone 8
Normalized name: dexamethasone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 8 mg, n = 40
Study: 18574679
Drug: Intensive intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive intervention (physician advice, in-person counseling with nicotine replacement therapy, 5 telephone calls)
Study: 17043424
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (intravenous cefotaxime 2 g q 8 hr for 7 days)
Study: 17043424
Drug: On-demand antibiotics
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand antibiotics (same antibiotics only when infection became evident)
Study: 7494588
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy in patients with preinfarction angina
Study: 7494588
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy in patients without preinfarction angina
Study: 1387927
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose of ondansetron (8-32 mg)
Study: 1387927
Drug: Single 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 8 mg i.v. dose of ondansetron
Study: 1387927
Drug: Single 32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 32 mg i.v. dose of ondansetron
Study: 1387927
Drug: Ondansetron dosing
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron dosing regimen (8-32 mg i.v. followed by 8 mg orally twice daily)
Study: 3993321
Drug: Metoclopramide 20
Normalized name: metoclopramide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 20 mg intravenously given at least 90 min before premedication
Study: 28676085
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of NeuroEPO every 8 hours for 4 days (Group A)
Study: 28676085
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of NeuroEPO every 8 hours for 4 days (Group B)
Study: 25584931
Drug: IR/ER HB/APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR/ER HB/APAP 45/1950 mg (intact)
Study: 25584931
Drug: IR/ER HB/APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR/ER HB/APAP 22.5/975 mg (intact)
Study: 25584931
Drug: Crushed IR/ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed IR/ER HB/APAP 45/1950 mg
Study: 21813293
Drug: Acarbose 50
Normalized name: acarbose 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 50 mg (titrated to 100 mg) three times daily
Study: 21813293
Drug: Glibenclamide 2.5
Normalized name: glibenclamide 2.5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide 2.5 mg (titrated to 5.0 mg) three times daily
Study: 16682542
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (TT) - 200 mg/mL of testosterone enanthate every 2 weeks for 8 weeks
Study: 16682542
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - isotonic sodium chloride solution injections
Study: 16682542
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (TT)
Study: 11369986
Drug: Modified fluid
Normalized name: modified fluid gelatin
DrugBank: Succinylated gelatin (DB16568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified fluid gelatin (1000 ml)
Study: 9160527
Drug: Single booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single booster dose of rabies vaccine
Study: 9160527
Drug: Rabies vaccine
Normalized name: RABIES VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabies vaccine (HDCV)
Study: 9160527
Drug: Rabies vaccine
Normalized name: RABIES VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabies vaccine (PCECV, PDEV, PVRV)
Study: 9160527
Drug: Rabies neutralizing
Normalized name: rabies virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabies neutralizing antibody
Study: 11001241
Drug: Pindolol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (2.5 mg three times daily)
Study: 9003110
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg/day, n = 151)
Study: 1468283
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of oral GP (glipizide) taken without food after 4 weeks of OD therapy
Study: 1468283
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of oral GB (glyburide) taken without food after 4 weeks of OD therapy
Study: 1468283
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of oral GP taken without food after 4 weeks of TD therapy
Study: 1468283
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of oral GB taken without food after 4 weeks of TD therapy
Study: 6138597
Drug: Metronidazole (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (250 mg four times a day for 10 days)
Study: 29749803
Drug: Laycarer prepares,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laycarer prepares, labels and stores injections
Study: 29749803
Drug: Registered nurse
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Registered nurse prepares injections
Study: 29749803
Drug: Pharmacist prepares
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist prepares injections
Study: 29749803
Drug: Laycarer preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laycarer preparation vs nurse or pharmacist preparation
Study: 15853281
Drug: Experiential-teaching method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experiential-teaching method entitled 'To be Touched by AIDS' with an affective component involving an African-American female who is an HIV-Positive intravenous drug user.
Study: 9559600
Drug: Hydrocortisone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (100 mg i.v. three times daily for 5 days)
Study: 7889608
Drug: Prolonged dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged dopamine infusion (5 micrograms/kg/min i.v.) for 83-296 hours
Study: 7889608
Drug: Brief dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief dopamine infusion (5 micrograms/kg/min i.v.) for 15-21 hours
Study: 3062558
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein formula (F1.3) containing 1.3 g protein/100 ml
Study: 3062558
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein formula (F1.8) containing 1.8 g protein/100 ml
Study: 11277602
Drug: Clomipramine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (mean dose 89.1 +/- 8.2 mg/day)
Study: 11277602
Drug: Clomipramine maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine maintenance treatment (full doses for 4-6 months)
Study: 11277602
Drug: Placebo substitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo substitution after tapering clomipramine
Study: 11277602
Drug: Clomipramine discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine discontinuation
Study: 31269902
Drug: Patient self-administered
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient self-administered questionnaires (SAQs)
Study: 27256731
Drug: High lead
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: High lead exposure group (cord blood lead >0.48 μmol/L)
Study: 27256731
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (cord blood lead <0.48 μmol/L)
Study: 23017356
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g n3-FA/day
Study: 20931547
Drug: Pluvio® (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pluvio® (a combination of plant extracts including avocado and soya oil, and a high dose of Urtica Dioica)
Study: 16110205
Drug: 1% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chlorhexidine (CHX) gel treatment
Study: 16110205
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo gel or no gel treatment)
Study: 12171954
Drug: Misoprostol 200
Normalized name: MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 200 micro g four times daily
Study: 7577205
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with bone marrow transplant
Study: 1823066
Drug: Cisapride, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride, 10 mg t.i.d. for 8 weeks
Study: 1823066
Drug: Ranitidine, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 150 mg b.i.d. for 8 weeks
Study: 6162015
Drug: Knowledge of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge of plasma levels of anti-epileptic drugs (Group A)
Study: 6162015
Drug: No knowledge
Approvals — FDA: no, EMA: no, PMDA: no
Description: No knowledge of plasma levels of anti-epileptic drugs (Group B)
Study: 26263223
Drug: Metformin (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (n = 28)
Study: 25468896
Drug: Lutein (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein (10 mg/d) and Zeaxanthin (2 mg/d)
Study: 21989119
Drug: Family-Based Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-Based Group Behavioral Treatment
Study: 17473202
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment (0.11 +/- 0.05 units/kg/d) plus best available palliative support
Study: 15185770
Drug: 0.6% amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6% amino acids/1.4% glycerol solution
Study: 15185770
Drug: 2.27% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.27% glucose solution (control)
Study: 9822092
Drug: bezafibrate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: bezafibrate (200 mg three times daily)
Study: 2572566
Drug: Bevantolol 200
Normalized name: bevantolol
DrugBank: Bevantolol (DB01295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevantolol 200 mg daily
Study: 2572566
Drug: Bevantolol 400
Normalized name: bevantolol
DrugBank: Bevantolol (DB01295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevantolol 400 mg daily
Study: 1149359
Drug: Propranolol (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.125 mg/kg)
Study: 25840499
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid fills
Study: 22739990
Drug: Adalimumab (ADA)
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab (ADA) plus Methotrexate (MTX) 15 mg/week
Study: 22739990
Drug: Placebo (PBO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PBO) plus Methotrexate (MTX) 15 mg/week
Study: 21190405
Drug: Web-based program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based program as an adjunct to educator-delivered prevention intervention
Study: 18329197
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (cromolyn sodium nasal spray)
Study: 18329197
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (cromolyn sodium nasal spray)
Study: 8390970
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate 1.0 g
Study: 8390970
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate 3.0 g
Study: 3089073
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (2-6 patches per day; mean 3.5)
Study: 31907002
Drug: Metta-based group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metta-based group meditation and individual cognitive behavioral therapy (MeCBT)
Study: 24755130
Drug: Morphine with
Normalized name: opium alkaloids with morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine with flurbiprofen
Study: 22890503
Drug: Xylitol gum
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylitol gum (mean 3.8 g/day, 2.9 times/day) for 13 months
Study: 19162389
Drug: Previously‐published meta‐analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previously‐published meta‐analysis of oral reading (11 studies)
Study: 17227801
Drug: Annual iv
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual iv administration of 4 mg zoledronate
Study: 10989241
Drug: Transdermal ethinyl
Normalized name: ethinyl estradiol / norelgestromin Transdermal System [Xulane]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal ethinyl estradiol (EE) in Group A (n=14)
Study: 10989241
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy in Group B (n=12)
Study: 8846126
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose 6-mercaptopurine (HD‐6MP) 1300 mg/m(2).24h
Study: 8846126
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose 6-mercaptopurine (HD‐6MP) 1300 mg/m(2).24h with allopurinol (200 mg/m(2).day)
Study: 1480728
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg once daily, titrated up to 200 mg if necessary)
Study: 24721352
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide inhalation
Study: 19836144
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR (300 mg/day for 6 weeks)
Study: 16604131
Drug: Desmopressin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin (30 microg intranasal administration) under no hydration (NH-Des)
Study: 12702129
Drug: SQV/RTV 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQV/RTV 1000 mg/100 mg twice daily (BID) as hard gelatin capsule (HGC) for 10 days
Study: 12702129
Drug: SQV/RTV 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQV/RTV 1000 mg/100 mg twice daily (BID) as soft gelatin capsule (SGC) for 10 days
Study: 3907277
Drug: Imipramine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine + Dixyrazine (50 mg/day)
Study: 3907277
Drug: Imipramine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine + Diazepam (10 mg/day)
Study: 28762106
Drug: Sertraline (part
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (part of a multicentre randomised placebo-controlled trial)
Study: 22283559
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg once daily for 12 days followed by DMQ 30 mg/30 mg twice daily for 8 days (Group 1)
Study: 22283559
Drug: DMQ 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMQ 30 mg/30 mg twice daily for 8 days followed by paroxetine 20 mg once daily for 12 days (Group 2)
Study: 22283559
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (DMQ + paroxetine)
Study: 22283559
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (paroxetine + DMQ)
Study: 20024591
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with hop rho iso-alpha acids (200 mg), berberine sulfate trihydrate (100 mg), vitamin D3 (500 IU), and vitamin K1 (500 mcg), twice daily
Study: 20024591
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with hop rho iso-alpha acids, berberine sulfate trihydrate, vitamin D3 and vitamin K1
Study: 16448251
Drug: Teeth washed
Normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teeth washed and immersed in iodine solution (experimental group)
Study: 6824149
Drug: Etomidate 100
Normalized name: metomidate 1000 mg in 1 g TOPICAL POWDER [Aquacalm]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate 100 micrograms/kg/minute with fentanyl 1 microgram/kg/minute for 10 minutes, followed by a maintenance dose at a rate of one-tenth this amount
Study: 24434529
Drug: Ecopipam 50
Normalized name: Ecopipam
DrugBank: Ecopipam (DB12273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecopipam 50 mg daily (weeks 1-2) and then 100 mg daily (weeks 3-8)
Study: 21946197
Drug: Heparin-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-free
Study: 11918249
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vibration and erotic videotape
Study: 3605735
Drug: MTC 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTC 0.03 mg/kg
Study: 3605735
Drug: Saline 0.015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0.015 ml/kg
Study: 17227498
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg on-demand
Study: 24171516
Drug: Autologous stem-cell
Normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous stem-cell transplantation after one additional cycle of induction chemotherapy
Study: 24171516
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (three additional cycles of induction chemotherapy)
Study: 19766757
Drug: Single-bolus intravenous
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-bolus intravenous administration of sodium bicarbonate (20 mEq) plus standard hydration with sodium chloride
Study: 14995938
Drug: Desflurane anaesthesia
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desflurane anaesthesia supplemented with intravenous remifentanil
Study: 2109643
Drug: Ibuprofen lysine
Normalized name: Ibuprofen Lysine
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen lysine 500 mg (oral administration)
Study: 2109643
Drug: Ibuprofen 200
Normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 200 mg (intravenous injection)